Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regard...
We raise '25e-'27e EBITDA by 35-40% on the recent SEK 1bn order 2025 will be a strong year: sales +1...
Prostatype räknar i en uppdaterad bedömning med att granskande part ska återkomma under 2025 med ett...
Karin Schreil, CEO, leaves her position at the end of 2025 She has implemented significant internal ...
Redeye briefly comments on yesterday’s news that the final reporting of the ELC-100 study will be po...
PTS has published new statistics for the SE fibre market BRE2 market share: 14% vs 13% in 2023 BRE2'...
Endomines published its updated strategy for 2025–2029, which largely builds on the previous one, wi...
Biovica sets precise sales targets after recording SEK 8.
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strateg...
Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional an...
Redeye provides a brief on yesterday’s news from Nitro Games, which announced that publishing rights...
Redeye initiates coverage of Xplora, a fast-growing family IoT company with a proven recurring reven...
Systemair redovisar ett stabilt fjärde kvartal 2024/25 med förbättrade marginaler och starkt kassafl...
Den välannonserade svackan i Q1 blev djupare än vi tänkt oss, men ruckar inte på bilden av ett välmå...
Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citize...
